These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8791122)

  • 1. Ethical issues of intervention trials in cancer.
    Sancho-Garnier H; Joseph R
    IARC Sci Publ; 1996; (136):121-2. PubMed ID: 8791122
    [No Abstract]   [Full Text] [Related]  

  • 2. [Socio-ethic of cancer chemoprevention].
    Sancho-Garnier H
    Bull Cancer; 2001 Apr; 88(4):411-4. PubMed ID: 11371376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
    Sanner T; Dybing E
    Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast cancer.
    Nayfield SG
    J Cell Biochem Suppl; 1996; 25():123-30. PubMed ID: 9027608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical issues: changing attitudes and practices.
    Henderson MM
    Cancer Detect Prev; 1994; 18(4):323-7. PubMed ID: 7982242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methodological issues in the design of primary prevention trials.
    Gaziano JM; Hennekens CH; Buring JE
    IARC Sci Publ; 1996; (136):7-12. PubMed ID: 8791110
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of human trial findings.
    Huttunen JK
    IARC Sci Publ; 1996; (139):271-6. PubMed ID: 8923037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer chemoprevention: how do we know what works?
    Neugut AI; Lebwohl B; Hershman DL
    J Clin Oncol; 2007 Apr; 25(12):1461-2. PubMed ID: 17442987
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemoprevention clinical trials: it is time to turn success into progress.
    Brown PH
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer prevention I: introduction.
    Dunn BK; Greenwald P
    Semin Oncol; 2010 Jun; 37(3):190-201. PubMed ID: 20709204
    [No Abstract]   [Full Text] [Related]  

  • 14. Data evaluation as a contribution to cancer prevention.
    Stewart BW
    IARC Sci Publ; 1996; (139):303-12. PubMed ID: 8923040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemoprevention of cancers].
    Espie M
    Bull Cancer; 1995 Jul; 82 Suppl 3():181s-185s. PubMed ID: 7492832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The trials of cancer chemoprevention.
    Lancet; 2005 Oct 29-Nov 4; 366(9496):1506. PubMed ID: 16257326
    [No Abstract]   [Full Text] [Related]  

  • 17. Behavioural intervention versus chemoprevention.
    Henderson M; Thompson B; Kristal A
    IARC Sci Publ; 1996; (136):123-30. PubMed ID: 8791123
    [No Abstract]   [Full Text] [Related]  

  • 18. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
    Lippman SM; Lee JJ
    Cancer Res; 2006 Mar; 66(6):2893-903. PubMed ID: 16540634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of human trial design.
    Buiatti E
    IARC Sci Publ; 1996; (139):261-9. PubMed ID: 8923036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
    Armstrong WB; Taylor TH; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.